Latest Hotspot

Merus Reports Initial Dosing in Phase 3 LiGeR-HN2 Trial of Petosemtamab for 2/3L r/m HNSCC

31 July 2024
3 min read

Merus N.V., a clinical-stage oncology company focused on developing groundbreaking full-length multispecific antibodies, has announced the enrollment of the first patient in its phase 3 trial. This trial aims to assess the efficacy and safety of petosemtamab, a Biclonics targeting EGFR and LGR5, in comparison to the investigator's choice of single-agent chemotherapy or cetuximab in patients who have previously been treated for recurrent or metastatic head and neck squamous cell carcinoma. This study is known as the LiGeR-HN2 trial.

👇Discover comprehensive information about this drug, from its R&D status, core patents, clinical trials to approval status in global countries, by simply clicking on the image below. Dive deep into our drug database now.

Merus has received feedback from the U.S. Food and Drug Administration (FDA) indicating that a dosage of 1500 mg of petosemtamab administered biweekly is suitable for further development in HNSCC, both as a standalone treatment and in combination with pembrolizumab.

"With the promising clinical results of petosemtamab in HNSCC and confirmation from the FDA on the dosage, we are thrilled to have commenced treating our first patient in the phase 3 trial for the 2nd/3rd line," stated Fabian Zohren, M.D., Ph.D., Chief Medical Officer at Merus. "We are confident that petosemtamab could establish a new standard of care for r/m HNSCC."

Known also as MCLA-158, petosemtamab is a Biclonics low-fucose human full-length IgG1 antibody that targets both the epidermal growth factor receptor (EGFR) and the leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5).

Petosemtamab is engineered to have three distinct mechanisms of action: it inhibits EGFR-dependent signaling, promotes EGFR internalization and degradation in cancer cells by binding to LGR5, and enhances antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).®

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

According to the data provided by the Synapse Database, As of July 30, 2024, there are 1 investigational drug for the EGFR and LGR5 targets, including 6 indications, 1 R&D institution involved, with related clinical trials reaching 2, and as many as 731 patents.

The highest phase of development for Petosemtamab is Phase 3, indicating advanced research and potential for regulatory approval in the near future. In terms of regulatory status, the drug has been granted Fast Track and Breakthrough Therapy designations, highlighting its potential for significant therapeutic advancement in the treatment of the aforementioned indications.

图形用户界面, 文本, 应用程序

描述已自动生成

Is Lecanemab approved by the FDA?
Drug Insights
3 min read
Is Lecanemab approved by the FDA?
30 July 2024
Lecanemab, marketed under the brand name Leqembi, was granted accelerated approval by the FDA on January 6, 2023.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Jul 30
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Jul 30
30 July 2024
Jul 30th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
Is Ublituximab approved by the FDA?
Drug Insights
3 min read
Is Ublituximab approved by the FDA?
30 July 2024
Ublituximab, marketed under the brand name Briumvi, is a CD20 monoclonal antibody used in the treatment of multiple sclerosis (MS). Ublituximab was approved by the FDA on December 28, 2022.
Read →
Rhythm Pharmaceuticals Initiates Phase 2 Trial for Oral MC4R Agonist LB54640 in Hypothalamic Obesity Patients
Latest Hotspot
3 min read
Rhythm Pharmaceuticals Initiates Phase 2 Trial for Oral MC4R Agonist LB54640 in Hypothalamic Obesity Patients
30 July 2024
Rhythm Pharmaceuticals Begins Dosing First Patients in Phase 2 Trial for Oral MC4R Agonist LB54640 Targeting Hypothalamic Obesity.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.